NEW YORK, Feb. 7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Antifungals Market to 2017 - Generic Erosion of Major Polyenes, Azoles, Allylamines and Echinocandins to Slow Value GrowthSummary
GBI Research, the leading business intelligence provider has released its latest research "Antifungals Market to 2017 - Generic Erosion of Major Polyenes, Azoles, Allylamines and Echinocandins to Slow Value Growth", which provides an insight into antifungals sales and price forecasts until 2017. The report examines the global antifungal therapies, treatment usage patterns and treatment flow algorithm. In addition, the geographical distribution of antifungal therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the Research and Development (R&D) pipeline and the potential future blockbusters until 2017 with in-depth analysis of the top three antifungal therapeutic indications, namely aspergillosis, dermatophytosis and candidiasis. Furthermore, it also includes the market forecasts and treatment usage patterns of these three therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&A) and licensing agreements involving antifungals therapies is also presented.In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by the GBI Research team of experts. GBI Research analysis shows that the global antifungals market was estimated at $9.4 billion in 2010, with a Compound Annual Growth Rate (CAGR) of 2.9% during 2002 and 2010. The antifungals market is dominated by generics. GBI Research forecasts that the market will grow at a CAGR of 1.9% during 2010-2017 to $10.8 billion. The patent expiry of a number of major drugs has paved way for the entry of generics. GBI Research analysis shows that the R&D pipeline for the antifungals market is not strong as it has become a generic market. Currently, only 38 molecules are in R&D, which indicates that antifungals R&D activity will not be very active for at least the next seven to eight years.